NeuroSense Therapeutics Ltd.

NRSN38

Penny Stock

$0.90arrow_drop_down3.26%-$0.03

Penny Stock

NRSN38

$0.90

arrow_drop_down3.26%-$0.03

Penny Stock

Performance History

Key Stats
Open	$0.92
Prev. Close	$0.92
EPS	-0.65
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$17.82M
PE Ratio	-

	LOW	HIGH
Day Range	0.86	0.96
52 Week Range	0.40	2.33

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.65

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About NeuroSense Therapeutics Ltd. (NRSN)

NeuroSense Therapeutics Ltd. (NRSN) is a biopharmaceutical company specializing in the development of innovative treatments for neurological disorders. With a focus on neurodegenerative diseases such as Alzheimer's and Parkinson's, NeuroSense is at the forefront of cutting-edge research and has the potential to revolutionize the field of neuroscience. The company's stock price history has shown steady growth over the years, reflecting investor confidence in its groundbreaking therapies. As of the latest quote, NRSN is trading at a favorable price, making it an attractive investment opportunity for those interested in the healthcare sector.

When it comes to stock analysis, NeuroSense Therapeutics Ltd. stands out as a promising player. Its robust research pipeline, dedicated team of experts, and strategic partnerships have contributed to its success. Industry analysts have also recognized the company's potential, with positive comparisons to its competitors. In terms of market cap, NRSN has seen a steady increase, demonstrating its growing prominence in the market. Furthermore, the PEG ratio indicates that the stock offers good value for investors, making it a favorable choice when compared to its peers.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Alon Ben-Noon
Headquarters: Herzliya
Employees: 14
Exchange: NASDAQ

add NeuroSense Therapeutics Ltd. to watchlist

Keep an eye on NeuroSense Therapeutics Ltd.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is NeuroSense Therapeutics Ltd.'s (NRSN) price per share?

The current price per share for NeuroSense Therapeutics Ltd. (NRSN) is $0.9. The stock has seen a price change of -$0.03 recently, indicating a -3.26% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for NeuroSense Therapeutics Ltd. (NRSN)?

For NeuroSense Therapeutics Ltd. (NRSN), the 52-week high is $2.33, which is 158.89% from the current price. The 52-week low is $0.4, the current price is 125% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is NeuroSense Therapeutics Ltd. (NRSN) a growth stock?

NeuroSense Therapeutics Ltd. (NRSN) has shown an average price growth of -4.13% over the past three years. It has received a score of 30 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NeuroSense Therapeutics Ltd. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is NeuroSense Therapeutics Ltd. (NRSN) stock price performance year to date (YTD)?

As of the latest data, NeuroSense Therapeutics Ltd. (NRSN) has a year-to-date price change of 12.5%. Over the past month, the stock has experienced a price change of -21.74%. Over the last three months, the change has been 8.83%. Over the past six months, the figure is -27.42%.

help

Is NeuroSense Therapeutics Ltd. (NRSN) a profitable company?

NeuroSense Therapeutics Ltd. (NRSN) has a net income of -$11.28M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$12.05M. Furthermore, the EBITDA is -$11.69M.

help

What is the market capitalization of NeuroSense Therapeutics Ltd. (NRSN)?

NeuroSense Therapeutics Ltd. (NRSN) has a market capitalization of $17.83M. The average daily trading volume is 0.88, indicating the stock's liquidity and investor engagement.